Herein, we provided in situ and ex vivo evidence indicating that T cell trafficking into the heart of patients with CCM may be supported by the in situ enhanced expression and/or deposition of fibronectin and TNF-α. The gene discussed is TNF; the disease is cerebral cavernous malformation.